Nerlynx: payments to doctors
Payments that named Nerlynx as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $5.1M
- Providers
- 7,918
- Transactions
- 25,198
- Average per transaction
- $204
The per-transaction average — $204 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,918 providers the average total is $650, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Puma Biotechnology, Inc. | $3,427,980 | 66.6% |
| PUMA Biotechnology, Inc. | $1,719,471 | 33.4% |